Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Importance of IgE antibody fraction size on allergen sensitivity of basophils from cat allergic patients on Xolair
2006-002771-40Phase 4Completed
- Sponsor
- SGO Johansson
- Start
- Jul 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of omalizumab in allergic asthma, allergic rhinitis (AR) and cat allergy, sponsored by SGO Johansson. Primary endpoint: Basophil cat allergen threshold sensitivity change. Started Jul 2006; status: completed.
02
Drugs
omalizumab
03
Conditions
allergic asthmaallergic rhinitis (AR)cat allergy
Beyond the preview
Go deeper on 2006-002771-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002771-40.